BioLineRx Enrols First Patient In Phase 1/2 Trial Of BL-7010

(RTTNews) - BioLineRx (BLRX), a clinical-stage biopharmaceutical company, announced enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease.

The first patient was enrolled at Tampere Hospital in Finland, a leading site for celiac disease research. Results are expected in the middle of 2014.

The Phase 1/2 study is a two-part, double-blind, placebo-controlled, dose escalation study of BL-7010 in up to 32 patients.

The primary objective is to assess the safety of single and repeated ascending doses of BL-7010 in well-controlled celiac patients. Secondary objectives include an assessment of the systemic exposure, if any, of BL-7010 in these patients.